Thymus cancer is a tumor formed on the outer surface originating from the epithelial cells of the thymus. The thymus is a small organ that is located in the upper chest under the breast region. Thymus cancer is uncommon cancer known for its association with the neuromuscular disorder myasthenia gravis and is found in 20% of patients with myasthenia gravis.
Download free sample @ https://www.datamintelligence.com/download-sample/thymus-cancer-market
The major driving forces are the increasing prevalence of thymic cancer, growing demand for technological advancements, innovative treatments, and increasing government initiatives.
The increasing prevalence of thymic cancer is expected to boost the market. For instance, according to the Cancer.net (American Society of Clinical Oncology), less than one person per 1.5 million people develops thymic cancer. This means about 400 people per year acquires thymoma. However, the exact number is not known and may be increased using computed tomohy scans. Thymoma is very raunting for less than, 1andn the thymus. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to enhance the growth of the thymus cancer market.
The presence of ongoing research activities is expected to boost the market.
The side effects related to the treatment of thymus cancer are expected to restrain the market. For instance, as per the American Cancer Society, radiation can damage the bone marrow leading to low blood counts. This can also lead to anemia (low red blood cell counts) and low white blood cell counts, which increases the risk of severe infections. Also, chest radiation therapy of the lungs. This may lead to trouble breathing and shortness of breath. This usually gets better after the radiation treatments stop, but sometimes the damage is long-term (or even permanent). Thus, the onset of side effects is likely to hamper the market.However, the high cost of treatment and the side effects of the treatment of thymus cancer is likely to hinder the growth of the thymus cancer market.
View full report @ https://www.datamintelligence.com/research-report/thymus-cancer-market
The key players operating in the global thymus cancer market are Cellceutix Corporation, Merck & Co., Novartis AG, Boston Biomedical, Inc., (Sumitomo Dainippon Pharma Co., Ltd.), Tiziana Life Sciences PLC, Karyopharm, Nerviano Medical Sciences S.r.l., and Pfizer.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the thymus cancer market globally. For instance,
On June 1, 2018, Boston Biomedical, Inc., announced that it would present the new research evaluating the investigational compound napabucasin in the treatment of multiple cancers, including advanced gastric and gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and advanced thymoma and thymic carcinoma at the 2018 American Society of Clinical Oncology Annual Meeting, held in Chicago from June 1-5, 2018.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States